← Issue №12/ week of Sep 20, 2026/Hepatology

Longitudinal gut microbiome dynamics during immunotherapy identify microbial features of clinical benefit in advanced primary liver cancer.

From GI Signals issue №12: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=315 · Sep 16, 2026 · Gut · IF 24.6

Longitudinal gut microbiome dynamics during immunotherapy identify microbial features of clinical benefit in advanced primary liver cancer.

Diagnosticmicrobiomebiomarkertranslationalbasic science
Clinical takeawayNo clinical action yet: a biomarker finding requiring validation before clinical use in liver cancer immunotherapy.
ContextExtends prior links between baseline microbiome and ICI response by showing dynamic on-treatment microbial remodeling improves prediction.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Qian Z … Lu Y · Gut · IF 24.6 · PubMed ↗Permalink
← Read the whole of issue №12 Every paper GI Signals surfaces gets a page like this one. All issues